Logo image of PROC

PROCAPS GROUP SA (PROC) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:PROC - LU2376511205 - Common Stock

1.01 USD
-0.58 (-36.51%)
Last: 2/3/2025, 8:00:01 PM
0.9501 USD
-0.06 (-5.93%)
After Hours: 2/3/2025, 8:00:01 PM

PROC Key Statistics, Chart & Performance

Key Statistics
Market Cap113.95M
Revenue(TTM)N/A
Net Income(TTM)52.19M
Shares112.82M
Float19.15M
52 Week High3.84
52 Week Low0.5
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2019-12-09
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PROC short term performance overview.The bars show the price performance of PROC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

PROC long term performance overview.The bars show the price performance of PROC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PROC is 1.01 USD. In the past month the price decreased by -56.65%. In the past year, price decreased by -68.92%.

PROCAPS GROUP SA / PROC Daily stock chart

PROC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.61 1.01T
JNJ JOHNSON & JOHNSON 19.89 497.52B
MRK MERCK & CO. INC. 11.97 261.73B
PFE PFIZER INC 7.83 142.45B
BMY BRISTOL-MYERS SQUIBB CO 8.16 109.00B
ZTS ZOETIS INC 19.61 54.78B
RPRX ROYALTY PHARMA PLC- CL A 9.33 22.14B
VTRS VIATRIS INC 5.3 14.22B
ELAN ELANCO ANIMAL HEALTH INC 23.02 10.98B
AXSM AXSOME THERAPEUTICS INC N/A 8.90B
BLTE BELITE BIO INC - ADR N/A 5.57B
CRNX CRINETICS PHARMACEUTICALS IN N/A 4.39B

About PROC

Company Profile

PROC logo image Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

Company Info

PROCAPS GROUP SA

9, rue de Bitbourg

Luxembourg LU

CEO: Kyle P. Bransfield

Employees: 5500

PROC Company Website

PROC Investor Relations

PROCAPS GROUP SA / PROC FAQ

What does PROCAPS GROUP SA do?

Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.


Can you provide the latest stock price for PROCAPS GROUP SA?

The current stock price of PROC is 1.01 USD. The price decreased by -36.51% in the last trading session.


Does PROC stock pay dividends?

PROC does not pay a dividend.


What is the ChartMill rating of PROCAPS GROUP SA stock?

PROC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the GICS sector and industry of PROC stock?

PROCAPS GROUP SA (PROC) operates in the Health Care sector and the Pharmaceuticals industry.


PROC Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PROC. When comparing the yearly performance of all stocks, PROC is a bad performer in the overall market: 96.48% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PROC Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

PROC Forecast & Estimates

6 analysts have analysed PROC and the average price target is 5.1 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 1.01.


Analysts
Analysts43.33
Price Target5.1 (404.95%)
EPS Next YN/A
Revenue Next YearN/A

PROC Ownership

Ownership
Inst Owners2.94%
Ins Owners0.13%
Short Float %N/A
Short RatioN/A